Takeaway

• In men with hypogonadism, short-term testosterone treatment does not appear to increase cardiovascular or cerebrovascular event risk.
• Longer-term effects, if any, are unknown.
• Editorial advises waiting for 5-year TRAVERSE trial results before widespread testosterone therapy adoption.

Why this matters

• Testosterone has a variety of potentially contrasting influences on cardiovascular...